Format
Sort by
Items per page

Send to

Choose Destination

Best matches for kynurenine 3-monooxygenase schizophrenia:

Search results

Items: 1 to 20 of 28

1.

Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: Relevance for schizophrenia.

Tufvesson-Alm M, Schwieler L, Schwarcz R, Goiny M, Erhardt S, Engberg G.

Neuropharmacology. 2018 Aug;138:130-139. doi: 10.1016/j.neuropharm.2018.06.003. Epub 2018 Jun 5.

PMID:
29879409
2.

Effect of Kynurenic Acid on Pupae Viability of Drosophila melanogaster cinnabar and cardinal Eye Color Mutants with Altered Tryptophan-Kynurenine Metabolism.

Navrotskaya V, Wnorowski A, Turski W, Oxenkrug G.

Neurotox Res. 2018 Aug;34(2):324-331. doi: 10.1007/s12640-018-9891-5. Epub 2018 Apr 4.

PMID:
29619629
3.

LPS-induced cortical kynurenic acid and neurogranin-NFAT signaling is associated with deficits in stimulus processing during Pavlovian conditioning.

Oliveros A, Wininger K, Sens J, Larsson MK, Liu XC, Choi S, Faka A, Schwieler L, Engberg G, Erhardt S, Choi DS.

J Neuroimmunol. 2017 Dec 15;313:1-9. doi: 10.1016/j.jneuroim.2017.09.010. Epub 2017 Sep 28.

PMID:
29153599
4.

The inhibition of the kynurenine pathway prevents behavioral disturbances and oxidative stress in the brain of adult rats subjected to an animal model of schizophrenia.

Réus GZ, Becker IRT, Scaini G, Petronilho F, Oses JP, Kaddurah-Daouk R, Ceretta LB, Zugno AI, Dal-Pizzol F, Quevedo J, Barichello T.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Feb 2;81:55-63. doi: 10.1016/j.pnpbp.2017.10.009. Epub 2017 Oct 13.

PMID:
29030243
5.

Peripheral kynurenine-3-monooxygenase deficiency as a potential risk factor for metabolic syndrome in schizophrenia patients.

Oxenkrug G, van der Hart M, Roeser J, Summergrad P.

Integr Clin Med. 2017;1(1). doi: 10.15761/ICM.1000105. Epub 2017 May 10.

6.

Serum kynurenic acid is reduced in affective psychosis.

Wurfel BE, Drevets WC, Bliss SA, McMillin JR, Suzuki H, Ford BN, Morris HM, Teague TK, Dantzer R, Savitz JB.

Transl Psychiatry. 2017 May 2;7(5):e1115. doi: 10.1038/tp.2017.88.

7.

Adaptive and Behavioral Changes in Kynurenine 3-Monooxygenase Knockout Mice: Relevance to Psychotic Disorders.

Erhardt S, Pocivavsek A, Repici M, Liu XC, Imbeault S, Maddison DC, Thomas MAR, Smalley JL, Larsson MK, Muchowski PJ, Giorgini F, Schwarcz R.

Biol Psychiatry. 2017 Nov 15;82(10):756-765. doi: 10.1016/j.biopsych.2016.12.011. Epub 2016 Dec 16.

8.

The kynurenine pathway in schizophrenia and bipolar disorder.

Erhardt S, Schwieler L, Imbeault S, Engberg G.

Neuropharmacology. 2017 Jan;112(Pt B):297-306. doi: 10.1016/j.neuropharm.2016.05.020. Epub 2016 May 28. Review.

PMID:
27245499
10.

Overview of the role of vitamins and minerals on the kynurenine pathway in health and disease.

Majewski M, Kozlowska A, Thoene M, Lepiarczyk E, Grzegorzewski WJ.

J Physiol Pharmacol. 2016 Feb;67(1):3-19. Review.

11.

Altered hippocampal plasticity by prenatal kynurenine administration, kynurenine-3-monoxygenase (KMO) deletion or galantamine.

Forrest CM, McNair K, Pisar M, Khalil OS, Darlington LG, Stone TW.

Neuroscience. 2015 Dec 3;310:91-105. doi: 10.1016/j.neuroscience.2015.09.022. Epub 2015 Sep 10.

12.

Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway.

Dounay AB, Tuttle JB, Verhoest PR.

J Med Chem. 2015 Nov 25;58(22):8762-82. doi: 10.1021/acs.jmedchem.5b00461. Epub 2015 Aug 5. Review.

PMID:
26207924
13.

Cerebrospinal fluid monoamine metabolite concentrations as intermediate phenotypes between glutamate-related genes and psychosis.

Andreou D, Söderman E, Axelsson T, Sedvall GC, Terenius L, Agartz I, Jönsson EG.

Psychiatry Res. 2015 Sep 30;229(1-2):497-504. doi: 10.1016/j.psychres.2015.06.023. Epub 2015 Jun 27.

14.

The kynurenine pathway and neurodegenerative disease.

Maddison DC, Giorgini F.

Semin Cell Dev Biol. 2015 Apr;40:134-41. doi: 10.1016/j.semcdb.2015.03.002. Epub 2015 Mar 12. Review.

PMID:
25773161
15.

[Association of kynurenine-3-monooxygenase gene with schizophrenia].

Golimbet VE, Lezheiko TV, Alfimova MV, Abramova LI, Kondrat'ev NV.

Genetika. 2014 Jun;50(6):724-8. Russian.

PMID:
25715464
16.

Influence of kynurenine 3-monooxygenase (KMO) gene polymorphism on cognitive function in schizophrenia.

Wonodi I, McMahon RP, Krishna N, Mitchell BD, Liu J, Glassman M, Hong LE, Gold JM.

Schizophr Res. 2014 Dec;160(1-3):80-7. doi: 10.1016/j.schres.2014.10.026. Epub 2014 Nov 14.

17.

Modified neocortical and cerebellar protein expression and morphology in adult rats following prenatal inhibition of the kynurenine pathway.

Pisar M, Forrest CM, Khalil OS, McNair K, Vincenten MC, Qasem S, Darlington LG, Stone TW.

Brain Res. 2014 Aug 12;1576:1-17. doi: 10.1016/j.brainres.2014.06.016. Epub 2014 Jun 21.

PMID:
24956103
18.

Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain.

Giorgini F, Huang SY, Sathyasaikumar KV, Notarangelo FM, Thomas MA, Tararina M, Wu HQ, Schwarcz R, Muchowski PJ.

J Biol Chem. 2013 Dec 20;288(51):36554-66. doi: 10.1074/jbc.M113.503813. Epub 2013 Nov 4.

19.

Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis.

Myint AM, Kim YK.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:304-13. doi: 10.1016/j.pnpbp.2013.08.008. Epub 2013 Oct 31. Review.

PMID:
24184687
20.

Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine.

Johansson AS, Owe-Larsson B, Asp L, Kocki T, Adler M, Hetta J, Gardner R, Lundkvist GB, Urbanska EM, Karlsson H.

J Psychiatr Res. 2013 Nov;47(11):1815-23. doi: 10.1016/j.jpsychires.2013.08.008. Epub 2013 Aug 23.

PMID:
24012176

Supplemental Content

Loading ...
Support Center